Model prediction on patient-specific IM discontinuation strategy based on individual BCR-ABL transcript kinetics. (A) Whereas the standard strategy, that is, fixed 2-year IM treatment in MR^5.0 before therapy discontinuation, is depicted by the dashed line, the result obtained by the proposed alternative strategy based on a patient-specific stopping rule is shown by the solid line. The dotted line represents a fixed 2.8-year IM treatment in MR^5.0, motivated by the median treatment time within the cohort in the individualized strategy. In all scenarios, the majority of relapsing patients is predicted to relapse within the first 6 months after IM discontinuation. The relapse rates predict a superior outcome of the personalized predictor-based strategy. (B) Distribution of individual times in MR^5.0 for the IRIS cohort before treatment cessation is recommended in the in silico patient-specific discontinuation strategy in panel A (solid line). Median treatment time is estimated to be 2.8 (range, 0.3-20.5) years.